Eosinophilic Esophagitis: Existing and Upcoming Therapies in an Age of Emerging Molecular and Personalized Medicine

Abstract

Purpose of Review

Recent research efforts have spurred great progress in the diagnosis and management of eosinophilic esophagitis (EoE). Nonetheless, challenges remain in addressing disease burden and impairment in the growing EoE population. We highlight work from the Cincinnati Center for Eosinophilic Disorders, the Consortium of Eosinophilic Gastrointestinal Disease Researchers, and others that address these ongoing challenges.

Recent Findings

New tools for characterizing EoE disease activity include the EoE Histology Scoring System (EoEHSS), endoscopic alternatives, validated patient-reported outcome (PRO) questionnaires, and investigational biomarkers. These diagnostic and monitoring strategies have been complemented by advances in EoE therapy. Treatment modalities have refined the traditional approaches of dietary elimination, swallowed steroids, and proton pump inhibitors (PPI), and biologics offer promise for future treatment.

Summary

This review summarizes EoE advances in disease management and newly defined EoE endotypes that may serve as the foundation for EoE-personalized medicine.

This is a preview of subscription content, log in to check access.

Fig. 1

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.

    Kelly KJ, Lazenby AJ, Rowe PC, Yardley JH, Perman JA, Sampson HA. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. Gastroenterology. 1995;109(5):1503–12.

    CAS  Google Scholar 

  2. 2.

    • Dellon ES, Liacouras CA, Molina-Infante J, Furuta GT, Spergel JM, Zevit N, et al. Updated International Consensus Diagnostic Criteria for eosinophilic esophagitis: proceedings of the AGREE Conference. Gastroenterology. 2018;155(4):1022–33 e10 Most recent EoE consensus guidelines, incorporating PPI-REE into EoE diagnosis.

    PubMed  PubMed Central  Google Scholar 

  3. 3.

    Straumann A, Bauer M, Fischer B, Blaser K, Simon HU. Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J Allergy Clin Immunol. 2001;108(6):954–61.

    CAS  Google Scholar 

  4. 4.

    Pentiuk S, Putnam PE, Collins MH, Rothenberg ME. Dissociation between symptoms and histological severity in pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2009;48(2):152–60.

    PubMed  PubMed Central  Google Scholar 

  5. 5.

    DeBrosse CW, Collins MH, Buckmeier B, Greenburg A, Allen C, Abonia JP, et al., editors. The “epidemic” of eosinophilic esophagitis (ee) is due to increased recognition of a chronic disorder. J Allergy Clin Immunol; 2010.

  6. 6.

    Fujiwara Y, Sugawa T, Tanaka F, Tatsuwaki H, Okuyama M, Hayakawa T, et al. A multicenter study on the prevalence of eosinophilic esophagitis and PPI-responsive esophageal eosinophilic infiltration. Intern Med. 2012;51(23):3235–9.

    Google Scholar 

  7. 7.

    Nantes Castillejo O, Zozaya JM, Jimenez-Perez FJ, Martinez-Penuela JM, Borda F. Incidence and characteristics of eosinophilic esophagitis in adults. An Sist Sanit Navar. 2009;32(2):227–34.

    CAS  Google Scholar 

  8. 8.

    • Shoda T, Wen T, Aceves SS, Abonia JP, Atkins D, Bonis PA, et al. Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study. Lancet Gastroenterol Hepatol. 2018;3(7):477–88 Identifies defined endotypes within EoE.

    PubMed  PubMed Central  Google Scholar 

  9. 9.

    Dunn JL, Shoda T, Caldwell JM, Wen T, Aceves SS, Collins MH, et al. Esophageal type 2 cytokine expression heterogeneity in eosinophilic esophagitis in a multi-site cohort. J Allergy Clin Immunol. 2020.

  10. 10.

    Collins MH, Martin LJ, Alexander ES, Boyd JT, Sheridan R, He H, et al. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. Dis Esophagus. 2017;30(3):1–8.

    CAS  Google Scholar 

  11. 11.

    Hirano I, Collins MH, Assouline-Dayan Y, Evans L, Gupta S, Schoepfer AM, et al. RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis. Gastroenterology. 2019;156(3):592–603. e10.

    CAS  Google Scholar 

  12. 12.

    • Hirano I, Dellon ES, Hamilton JD, Collins MH, Peterson K, Chehade M, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158(1):111–22. e10 Phase 2 results of dupilumab in EoE.

    CAS  Google Scholar 

  13. 13.

    Zaccariello MJ, Frank RD, Lee M, Kirsch AC, Schroeder DR, Hanson AC, et al. Patterns of neuropsychological changes after general anaesthesia in young children: secondary analysis of the Mayo Anesthesia Safety in Kids study. Br J Anaesth. 2019;122(5):671–81.

    PubMed  PubMed Central  Google Scholar 

  14. 14.

    Postma GN, Cohen JT, Belafsky PC, Halum SL, Gupta SK, Bach KK, et al. Transnasal esophagoscopy: revisited (over 700 consecutive cases). Laryngoscope. 2005;115(2):321–3.

    Google Scholar 

  15. 15.

    Friedlander JA, DeBoer EM, Soden JS, Furuta GT, Menard-Katcher CD, Atkins D, et al. Unsedated transnasal esophagoscopy for monitoring therapy in pediatric eosinophilic esophagitis. Gastrointest Endosc. 2016;83(2):299–306. e1.

    Google Scholar 

  16. 16.

    Nguyen N, Lavery WJ, Capocelli KE, Smith C, DeBoer EM, Deterding R, et al. Transnasal endoscopy in unsedated children with eosinophilic esophagitis using virtual reality video goggles. J Clin Gastroenterol Hepatol. 2019;17(12):2455–62.

    Google Scholar 

  17. 17.

    Philpott H, Nandurkar S, Royce SG, Gibson PR. Ultrathin unsedated transnasal gastroscopy in monitoring eosinophilic esophagitis. J Gastroenterol Hepatol. 2016;31(3):590–4.

    Google Scholar 

  18. 18.

    Iqbal U, Siddique O, Ovalle A, Anwar H, Moss SF. Safety and efficacy of a minimally invasive cell sampling device (‘Cytosponge’) in the diagnosis of esophageal pathology: a systematic review. Eur J Gastroenterol Hepatol. 2018;30(11):1261–9.

    Google Scholar 

  19. 19.

    Katzka DA, Geno DM, Ravi A, Smyrk TC, Lao-Sirieix P, Miramedi A, et al. Accuracy, safety, and tolerability of tissue collection by Cytosponge vs endoscopy for evaluation of eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2015;13(1):77–83.e2.

    Google Scholar 

  20. 20.

    Katzka DA, Smyrk TC, Alexander JA, Geno DM, Beitia RA, Chang AO, et al. Accuracy and safety of the cytosponge for assessing histologic activity in eosinophilic esophagitis: a two-center study. Am J Gastroenterol. 2017;112(10):1538–44.

    PubMed  PubMed Central  Google Scholar 

  21. 21.

    Mayo Clinic. Cytosponge and dietary therapy in EoE. https://ClinicalTrials.gov/show/NCT02599558; 2015.

  22. 22.

    Hines BT, Rank MA, Wright BL, Marks LA, Hagan JB, Straumann A, et al. Minimally invasive biomarker studies in eosinophilic esophagitis: a systematic review. Ann Allergy Asthma Immunol. 2018;121(2):218–28.

    PubMed  PubMed Central  Google Scholar 

  23. 23.

    Mori Y, Iwasaki H, Kohno K, Yoshimoto G, Kikushige Y, Okeda A, et al. Identification of the human eosinophil lineage-committed progenitor: revision of phenotypic definition of the human common myeloid progenitor. J Exp Med. 2009;206(1):183–93.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Sehmi R, Smith S, Kjarsgaard M, Radford K, Boulet LP, Lemiere C, et al. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma. J Clin Exp Allergy. 2016;46(6):793–802.

    CAS  Google Scholar 

  25. 25.

    Morris DW, Stucke EM, Martin LJ, Abonia JP, Mukkada VA, Putnam PE, et al. Eosinophil progenitor levels are increased in patients with active pediatric eosinophilic esophagitis. J Allergy Clin Immunol. 2016;138(3):915–8 e5.

    PubMed  PubMed Central  Google Scholar 

  26. 26.

    Henderson A, Magier A, Schwartz JT, Martin LJ, Collins MH, Putnam PE, et al. Monitoring eosinophilic esophagitis disease activity with blood eosinophil progenitor levels. J Pediatr Gastroenterol Nutr. 2020;70(4):482–8.

    CAS  Google Scholar 

  27. 27.

    Schwartz JT, Morris DW, Collins MH, Rothenberg ME, Fulkerson PC. Eosinophil progenitor levels correlate with tissue pathology in pediatric eosinophilic esophagitis. J Allergy Clin Immunol. 2019;143(3):1221–4. e3.

    Google Scholar 

  28. 28.

    Thomas G, Goldsmid J, Wicks A. Use of the Enterotest duodenal capsule in the diagnosis of giardiasis. S Afr Med J. 1973;47(11):2219–20.

    Google Scholar 

  29. 29.

    Furuta GT, Kagalwalla AF, Lee JJ, Alumkal P, Maybruck BT, Fillon S, et al. The oesophageal string test: a novel, minimally invasive method measures mucosal inflammation in eosinophilic oesophagitis. Gut. 2013;62(10):1395–405.

    CAS  Google Scholar 

  30. 30.

    Ackerman SJ, Kagalwalla AF, Hirano I, Gonsalves N, Katcher PM, Gupta S, et al. One-hour esophageal string test: a nonendoscopic minimally invasive test that accurately detects disease activity in eosinophilic esophagitis. Am J Gastroenterol. 2019;114(10):1614–25.

    PubMed  PubMed Central  Google Scholar 

  31. 31.

    Patrick DL, Burke LB, Powers JH, Scott JA, Rock EP, Dawisha S, et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health. 2007;10:S125–S37.

    Google Scholar 

  32. 32.

    Schoepfer AM, Straumann A, Panczak R, Coslovsky M, Kuehni CE, Maurer E, et al. Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis. Gastroenterology. 2014;147(6):1255–66.e21.

    PubMed  PubMed Central  Google Scholar 

  33. 33.

    Schoepfer A, Safroneeva E. Activity assessment of eosinophilic esophagitis. Dig Dis. 2014;32(1–2):98–101.

    Google Scholar 

  34. 34.

    Aceves SS, King E, Collins MH, Yang GY, Capocelli KE, Abonia JP, et al. Alignment of parent- and child-reported outcomes and histology in eosinophilic esophagitis across multiple CEGIR sites. J Allergy Clin Immunol. 2018;142(1):130–8 e1.

    PubMed  PubMed Central  Google Scholar 

  35. 35.

    Franciosi JP, Hommel KA, DeBrosse CW, Greenberg AB, Greenler AJ, Abonia JP, et al. Development of a validated patient-reported symptom metric for pediatric eosinophilic esophagitis: qualitative methods. BMC Gastroenterol. 2011;11:126.

    PubMed  PubMed Central  Google Scholar 

  36. 36.

    Franciosi JP, Hommel KA, Bendo CB, King EC, Collins MH, Eby MD, et al. PedsQL eosinophilic esophagitis module: feasibility, reliability, and validity. J Pediatr Gastroenterol Nutr. 2013;57(1):57–66.

    PubMed  PubMed Central  Google Scholar 

  37. 37.

    Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113(1):59–65.

    Google Scholar 

  38. 38.

    Arias A, Gonzalez-Cervera J, Tenias JM, Lucendo AJ. Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis. Gastroenterology. 2014;146(7):1639–48.

    Google Scholar 

  39. 39.

    Markowitz JE, Spergel JM, Ruchelli E, Liacouras CA. Elemental diet is an effective treatment for eosinophilic esophagitis in children and adolescents. Am J Gastroenterol. 2003;98(4):777–82.

    CAS  Google Scholar 

  40. 40.

    Gonsalves N. Food allergies and eosinophilic gastrointestinal illness. Gastroenterol Clin North Am. 2007;36(1):75–91 vi.

    Google Scholar 

  41. 41.

    Kagalwalla AF, Sentongo TA, Ritz S, Hess T, Nelson SP, Emerick KM, et al. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2006;4(9):1097–102.

    Google Scholar 

  42. 42.

    Spergel JM, Brown-Whitehorn TF, Cianferoni A, Shuker M, Wang ML, Verma R, et al. Identification of causative foods in children with eosinophilic esophagitis treated with an elimination diet. J Allergy Clin Immunol. 2012;130(2):461–7 e5.

    Google Scholar 

  43. 43.

    Lucendo AJ, Arias A, Gonzalez-Cervera J, Yague-Compadre JL, Guagnozzi D, Angueira T, et al. Empiric 6-food elimination diet induced and maintained prolonged remission in patients with adult eosinophilic esophagitis: a prospective study on the food cause of the disease. J Allergy Clin Immunol. 2013;131(3):797–804.

    Google Scholar 

  44. 44.

    Dellon ES, Gonsalves N, Hirano I, Furuta GT, Liacouras CA, Katzka DA, et al. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol. 2013;108(5):679–92.

    Google Scholar 

  45. 45.

    Henderson CJ, Collins MH, Abonia JP, Putnam PE, Rothenberg ME. Reply: To PMID 22541246. J Allergy Clin Immunol. 2013;131(1):243–4.

    Google Scholar 

  46. 46.

    Henderson CJ, Abonia JP, King EC, Putnam PE, Collins MH, Franciosi JP, et al. Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. J Allergy Clin Immunol. 2012;129(6):1570–8.

    PubMed  PubMed Central  Google Scholar 

  47. 47.

    Chehade M, Jones SM, Pesek RD, Burks AW, Vickery BP, Wood RA, et al. Phenotypic characterization of eosinophilic esophagitis in a large multicenter patient population from the consortium for food allergy research. J Allergy Clin Immunol Pract. 2018;6(5):1534–44 e5.

    PubMed  PubMed Central  Google Scholar 

  48. 48.

    Wolf WA, Huang KZ, Durban R, Iqbal ZJ, Robey BS, Khalid FJ, et al. The six-food elimination diet for eosinophilic esophagitis increases grocery shopping cost and complexity. Dysphagia. 2016;31(6):765–70.

    Google Scholar 

  49. 49.

    Kagalwalla AF, Wechsler JB, Amsden K, Schwartz S, Makhija M, Olive A, et al. Efficacy of a 4-food elimination diet for children with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2017;15(11):1698–707. e7.

    PubMed  PubMed Central  Google Scholar 

  50. 50.

    Molina-Infante J, Arias A, Barrio J, Rodriguez-Sanchez J, Sanchez-Cazalilla M, Lucendo AJ. Four-food group elimination diet for adult eosinophilic esophagitis: a prospective multicenter study. J Allergy Clin Immunol. 2014;134:1093–1099.e1.

    Google Scholar 

  51. 51.

    Molina-Infante J, Arias A, Alcedo J, Garcia-Romero R, Casabona-Frances S, Prieto-Garcia A, et al. Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: the 2-4-6 study. J Allergy Clin Immunol. 2018;141(4):1365–72.

    Google Scholar 

  52. 52.

    Cincinnati Children’s Hospital Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Allergy and Infectious Diseases, Office of Rare Diseases, National Center for Advancing Translational Science. SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study. https://ClinicalTrials.gov/show/NCT02778867; 2016.

  53. 53.

    Cincinnati Children’s Hospital Medical Center, Patient-Centered Outcomes Research Institute. Eosinophilic esophagitis intervention trial-1 food vs. 4 food elimination diet followed by swallowed glucocorticoids. https://ClinicalTrials.gov/show/NCT02610816; 2016.

  54. 54.

    Dellon ES, Woosley JT, Arrington A, McGee SJ, Covington J, Moist SE, et al. Efficacy of budesonide vs fluticasone for initial treatment of eosinophilic esophagitis in a randomized controlled trial. Gastroenterology. 2019;157(1):65–73. e5.

    CAS  Google Scholar 

  55. 55.

    Gupta SK, Vitanza JM, Collins MH. Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2015;13(1):66–76. e3.

    CAS  Google Scholar 

  56. 56.

    Murali AR, Gupta A, Attar BM, Ravi V, Koduru P. Topical steroids in eosinophilic esophagitis: systematic review and meta-analysis of placebo-controlled randomized clinical trials. J Gastroenterol Hepatol. 2016;31(6):1111–9.

    CAS  Google Scholar 

  57. 57.

    Alexander JA, Jung KW, Arora AS, Enders F, Katzka DA, Kephardt GM, et al. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2012;10(7):742–9. e1.

    CAS  Google Scholar 

  58. 58.

    Ryrfeldt Å, Andersson P, Edsbäcker S, Tönnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis. 1982;122:86–95.

    CAS  Google Scholar 

  59. 59.

    Harding S. The human pharmacology of fluticasone propionate. Respir Med. 1990;84:25–9.

    Google Scholar 

  60. 60.

    Golekoh MC, Hornung LN, Mukkada VA, Khoury JC, Putnam PE, Backeljauw PF. Adrenal insufficiency after chronic swallowed glucocorticoid therapy for eosinophilic esophagitis. J Pediatr. 2016;170:240–5.

    CAS  Google Scholar 

  61. 61.

    Hsu S, Wood C, Pan Z, Rahat H, Zeitler P, Fleischer D, et al. Adrenal insufficiency in pediatric eosinophilic esophagitis patients treated with swallowed topical steroids. Pediatr Allergy Immunol Pulmonol. 2017;30(3):135–40.

    PubMed  PubMed Central  Google Scholar 

  62. 62.

    Cotton CC, Eluri S, Wolf WA, Dellon ES. Six-food elimination diet and topical steroids are effective for eosinophilic esophagitis: a meta-regression. Dig Dis Sci. 2017;62(9):2408–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. 63.

    Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, Putnam PE, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology. 2007;133(4):1342–63.

    CAS  Google Scholar 

  64. 64.

    Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011;128(1):3–20 e6 quiz 1-2.

  65. 65.

    Spechler SJ, Genta RM, Souza RF. Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am J Gastroenterol. 2007;102(6):1301–6.

    CAS  Google Scholar 

  66. 66.

    Dellon ES, Speck O, Woodward K, Gebhart JH, Madanick RD, Levinson S, et al. Clinical and endoscopic characteristics do not reliably differentiate PPI-responsive esophageal eosinophilia and eosinophilic esophagitis in patients undergoing upper endoscopy: a prospective cohort study. Am J Gastroenterol. 2013;108(12):1854–60.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. 67.

    Wen T, Dellon ES, Moawad FJ, Furuta GT, Aceves SS, Rothenberg ME. Transcriptome analysis of proton pump inhibitor–responsive esophageal eosinophilia reveals proton pump inhibitor–reversible allergic inflammation. J Allergy Clin Immunol. 2015;135(1):187–97. e4.

    CAS  Google Scholar 

  68. 68.

    Wang L, Li M, Cao Y, Han Z, Wang X, Atkinson EJ, et al. Proton pump inhibitors and the risk for fracture at specific sites: data mining of the FDA adverse event reporting system. Sci Rep. 2017;7(1):5527.

    PubMed  PubMed Central  Google Scholar 

  69. 69.

    Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood. 1992;79(12):3101–9.

    CAS  Google Scholar 

  70. 70.

    Stein ML, Collins MH, Villanueva JM, Kushner JP, Putnam PE, Buckmeier BK, et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol. 2006;118(6):1312–9.

    CAS  Google Scholar 

  71. 71.

    Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut. 2010;59(01):21–30.

    CAS  Google Scholar 

  72. 72.

    Assa’ad AH, Gupta SK, Collins MH, Thomson M, Heath AT, Smith DA, et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology. 2011;141(5):1593–604.

    Google Scholar 

  73. 73.

    Spergel JM, Rothenberg ME, Collins MH, Furuta GT, Markowitz JE, Fuchs G 3rd, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012;129(2):456–63 63 e1–3.

    CAS  Google Scholar 

  74. 74.

    Ghazi A, Trikha A, Calhoun WJ. Benralizumab–a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity–a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012;12(1):113–8.

    CAS  Google Scholar 

  75. 75.

    Nutku E, Aizawa H, Hudson SA, Bochner BS. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood. 2003;101(12):5014–20.

    CAS  Google Scholar 

  76. 76.

    Cincinnati Children’s Hospital Medical Center, AstraZeneca. Benralizumab for Eosinophilic Gastritis. https://ClinicalTrials.gov/show/NCT03473977; 2018.

  77. 77.

    Allakos Inc. A study of antolimab (AK002) in patients with active eosinophilic esophagitis. https://ClinicalTrials.gov/show/NCT04322708; 2020.

  78. 78.

    Zuo L, Fulkerson PC, Finkelman FD, Mingler M, Fischetti CA, Blanchard C, et al. IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13Rα2–inhibited pathway. J Immunol. 2010;185(1):660–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  79. 79.

    Blanchard C, Mingler MK, Vicario M, Abonia JP, Wu YY, Lu TX, et al. IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. J Allergy Clin Immunol. 2007;120(6):1292–300.

    CAS  Google Scholar 

  80. 80.

    Rothenberg ME, Wen T, Greenberg A, Alpan O, Enav B, Hirano I, et al. Intravenous anti–IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015;135(2):500–7.

    CAS  Google Scholar 

  81. 81.

    Dellon ES, Collins MH, Rothenberg ME, Assouline-Dayan Y, Evans L, Gupta S, et al. Long-term efficacy and tolerability of RPC4046 in an open-label extension trial of patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2020.

  82. 82.

    Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–66.

    CAS  Google Scholar 

  83. 83.

    Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–48.

    CAS  Google Scholar 

  84. 84.

    Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469–79.

    CAS  Google Scholar 

  85. 85.

    Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–96.

    CAS  Google Scholar 

  86. 86.

    Vermeire S, Loftus EV, Colombel J-F, Feagan BG, Sandborn WJ, Sands BE, et al. Long-term efficacy of vedolizumab for Crohn’s disease. Journal of Crohn’s Colitis. 2017;11(4):412–24.

    Google Scholar 

  87. 87.

    Rafiee P, Ogawa H, Heidemann J, Li MS, Aslam M, Lamirand TH, et al. Isolation and characterization of human esophageal microvascular endothelial cells: mechanisms of inflammatory activation. Am J Physiol Gastrointest Liver Physiol. 2003;285(6):G1277–G92.

    CAS  Google Scholar 

  88. 88.

    Nhu QM, Chiao H, Moawad FJ, Bao F, Konijeti GG. The anti-alpha4beta7 integrin therapeutic antibody for inflammatory bowel disease, vedolizumab, ameliorates Eosinophilic esophagitis: a novel clinical observation. Am J Gastroenterol. 2018;113:1261–3.

    Google Scholar 

  89. 89.

    Taft TH, Mutlu EA. The potential role of vedolizumab in concomitant eosinophilic esophagitis and Crohn’s disease. Clin Gastroenterol Hepatol. 2018;16(11):1840–1.

    Google Scholar 

  90. 90.

    Kim HP, Reed CC, Herfarth HH, Dellon ES. Vedolizumab treatment may reduce steroid burden and improve histology in patients with eosinophilic gastroenteritis. Clin Gastroenterol Hepatol. 2018;16(12):1992–4.

    PubMed  PubMed Central  Google Scholar 

  91. 91.

    Abonia JP, Wen T, Stucke EM, Grotjan T, Griffith MS, Kemme KA, et al. High prevalence of eosinophilic esophagitis in patients with inherited connective tissue disorders. J Allergy Clin Immunol. 2013;132(2):378–86.

    Google Scholar 

  92. 92.

    Cincinnati Children’s Hospital Medical Center, Diabetes NIo, Digestive, Diseases K, Allergy NIo, Diseases I, et al. An open-label trial of losartan potassium in participants with eosinophilic esophagitis (EoE). https://ClinicalTrials.gov/show/NCT03029091; 2017.

  93. 93.

    Meester JA, Verstraeten A, Schepers D, Alaerts M, Van Laer L, Loeys BL. Differences in manifestations of Marfan syndrome, Ehlers-Danlos syndrome, and Loeys-Dietz syndrome. Ann Cardiothorac Surg. 2017;6(6):582–94.

    PubMed  PubMed Central  Google Scholar 

  94. 94.

    Ruiz-Ortega M, Rodríguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J. TGF-β signaling in vascular fibrosis. Cardiovasc Res. 2007;74(2):196–206.

    CAS  Google Scholar 

  95. 95.

    Ferguson AE, Mukkada VA, Fulkerson PC. Pediatric eosinophilic esophagitis endotypes: are we closer to predicting treatment response? Clin Rev Allergy Immunol. 2017.

  96. 96.

    Wen T, Stucke EM, Grotjan TM, Kemme KA, Abonia JP, Putnam PE, et al. Molecular diagnosis of eosinophilic esophagitis by gene expression profiling. Gastroenterology. 2013;145(6):1289–99.

    CAS  PubMed  PubMed Central  Google Scholar 

  97. 97.

    Dellon ES. Epidemiology of eosinophilic esophagitis. Gastroenterol Clin. 2014;43(2):201–18.

    Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to J. Pablo Abonia.

Ethics declarations

Conflict of Interest

Mrs. Hottinger reports grants from the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR; Administrative Core, U54AI117804), outside the submitted work. Dr. Mukkada reports consulting fees from Shire/Takeda, outside the submitted work. The other authors declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors. All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Pediatric Allergy and Immunology

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Slack, I.F., Schwartz, J.T., Mukkada, V.A. et al. Eosinophilic Esophagitis: Existing and Upcoming Therapies in an Age of Emerging Molecular and Personalized Medicine. Curr Allergy Asthma Rep 20, 30 (2020). https://doi.org/10.1007/s11882-020-00928-2

Download citation

Keywords

  • Eosinophilic esophagitis
  • Diagnosis
  • Treatment
  • Endotype